Pulmonary arterial hypertension (PAH) is a rare disease with an emerging genetic basis. Heterozygous mutations in the gene encoding the bone morphogenetic protein receptor type 2 (BMPR2) are the commonest genetic cause of PAH, whereas biallelic mutations in the eukaryotic translation initiation factor 2 alpha kinase 4 gene (EIF2AK4) are described in pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis. Here, we determine the frequency of these mutations and define the genotype-phenotype characteristics in a large cohort of patients diagnosed clinically with PAH.
P
ulmonary arterial hypertension (PAH) is a heterogeneous and rare disorder that can be classified into idiopathic and heritable forms, associated with an underlying condition such as connective tissue disease or congenital heart disease or related to specific drugs and toxins. 1, 2 In addition, pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis (PCH) are even rarer forms of pulmonary hypertension that are grouped together with PAH under the current classification system. 2 Clinical features described in patients with PVOD/PCH include a low transfer coefficient for carbon monoxide (Kco) and oxygen desaturation on exertion, as well as the presence of centrilobular ground glass opacification, interlobular septal thickening, and mediastinal lymphadenopathy on high-resolution computed tomography (CT) of the lung parenchyma. 3, 4 However, these clinical and radiological features have also been reported in idiopathic PAH. [5] [6] [7] Consequently, the clinical distinction between PVOD/PCH and idiopathic PAH can be challenging. It has been estimated that 10% of patients with PVOD/PCH are misdiagnosed as having idiopathic PAH. 8, 9 The diagnosis of PVOD/PCH is often confirmed only postmortem or from explanted lungs by histology.
The histological features of PVOD/PCH typically include pulmonary venous obstructions and pulmonary capillary proliferation, although the distribution of these changes within the lung can be heterogeneous. 10, 11 Pulmonary artery smooth muscle hypertrophy and intimal hyperplasia, similar to the changes observed in other forms of PAH, may also be present. Furthermore, pulmonary venous changes have been reported in cases of idiopathic PAH, patients with scleroderma-associated PAH, and those with BMPR2 mutations to varying extents. 12, 13 A major advance in the molecular diagnosis of PVOD/PCH was the finding of biallelic mutations in the gene encoding the eukaryotic translation initiation factor 2 alpha kinase 4 (EIF2AK4) in both familial (100%) and sporadic (20% to 25%) cases of PVOD/PCH. 14, 15 EI-F2AK4 is an activator of the integrated stress response pathway and responds to environmental stresses, including amino acid deprivation, by phosphorylating the α subunit of eukaryotic translation initiation factor 2. 11, 16, 17 These discoveries suggest that EIF2AK4 mutations are specific to PVOD/PCH and that finding biallelic EIF2AK4 mutations in a patient with pulmonary hypertension would be diagnostic of PVOD/PCH. Patients with PVOD/PCH have a poor prognosis and risk fatal pulmonary edema with the use of pulmonary artery vasodilator therapies. 4, [18] [19] [20] Consequently, early and accurate diagnosis is vital to guide clinical management.
Heterozygous mutations in the gene encoding the bone morphogenetic protein type 2 receptor (BMPR2) are the most common genetic cause of PAH. They are found in ≈17% of individuals with idiopathic PAH and 82% with a family history of the disease. 21 However, mutations in BMPR2 have also been reported in patients with histologically proven PVOD. 4, [22] [23] [24] Thus, considerable uncertainty remains as to what extent the finding of EIF2AK4 or BMPR2 mutations reliably predicts the clinical phenotype and response to therapy in a population of patients with PAH.
Here, we report the genetic and phenotypic characteristics of patients assessed for BMPR2 and EIF2AK4 mutations through whole-genome sequencing within a large cohort (n=880) of patients with PAH recruited to the National Institute of Health Research (NIHR) BRIDGE study (BioResource-Rare Diseases) ( Table I in the onlineonly Data Supplement). The frequency of mutations in other previously reported genes associated with PAH will be reported in a future publication. In this study, we identified and characterized patients with a clinical
Clinical Perspective
What Is New?
• One percent of patients with a clinical diagnosis of pulmonary arterial hypertension (PAH) carry biallelic EIF2AK4 mutations.
• Patients diagnosed clinically with PAH who had a transfer coefficient for carbon monoxide (Kco) <50% predicted and age of diagnosis <50 years were more likely to carry biallelic EIF2AK4 mutations. The diagnostic yield for genetic testing in this group was 53%.
• Radiological assessment was unable to distinguish reliably between these patients and patients with idiopathic PAH.
• Histology from these patients may show predominately pulmonary arteriopathy, with subtle involvement of the pulmonary veins and capillaries.
• Patients with PAH with biallelic EIF2AK4 mutations had a worse prognosis compared with other patients with PAH.
What Are the Clinical Implications?
• Younger patients diagnosed with idiopathic PAH but with a low Kco have a high frequency of biallelic EIF2AK4 mutations.
• Such patients should be reclassified as having pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis.
• Similar to patients with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis, these patients have a poor prognosis compared with other patients with PAH.
• The spectrum of radiological and histological changes associated with biallelic EIF2AK4 mutations is wider than previously assumed. The presence of only subtle or infrequent features associated with pulmonary veno-occlusive disease may lead to misclassification of these patients as having PAH.
• Genetic testing allows early identification of these patients, facilitating appropriate management.
and radiological diagnosis of idiopathic PAH who were found to possess biallelic EIF2AK4 mutations. These patients had a low Kco and were diagnosed at a younger age compared with patients with idiopathic PAH without mutations in these genes. We show that, in common with patients diagnosed clinically with PVOD/PCH, patients with PAH with biallelic EIF2AK4 mutations have a shorter survival. We conclude that clinical assessment alone is inadequate for the accurate diagnosis of PVOD/PCH. Clinical genetic testing in younger patients presenting clinically with PAH but with a low Kco will allow appropriate classification, leading to better risk stratification and management of these patients. 
METHODS Ethics Approval and Consent

Recruitment and Patients
The BRIDGE study is a prospective study recruiting both prevalent and incident patients with selected rare diseases. Recruitment to the BRIDGE PAH study started in January 2013, and the last patient included in this analysis was recruited on June 15, 2016. Patients with idiopathic PAH, heritable PAH, PVOD, and PCH, diagnosed according to international guidelines at specialist pulmonary hypertension centers in the United Kingdom, the Netherlands, and France, were recruited ( Figure 1 and Table II in the online-only Data Supplement). 2 This included 14 patients with confirmed mutations in BMPR2.
Throughout this article, we classify patients recruited to the study as having idiopathic PAH or familial PAH on the basis of the absence or presence of a family history of the disease. The term heritable PAH does not distinguish between patients with sporadic PAH with a mutation and patients with a mutation who have a family history. Therefore, the term heritable PAH is used only when referring to previous publications and guidelines.
Patients with other rare diseases and their unaffected relatives recruited to the BRIDGE study (Table III in Likely causal variants were identified on the basis of minor allele frequency and predicted deleteriousness. Variants were considered further if they had a minor allele frequency of <1 in 10 000 in unrelated BRIDGE control subjects without PAH and the ExAC database. 26 The rare variants that passed the minor allele frequency filtering were then assessed for deleteriousness. Variants were considered pathogenic on the basis of a combined annotation-dependent depletion score of ≥15 and PolyPhen-2 or sorting intolerant from tolerant predictions not classified as benign or tolerated, respectively.
27-29
Overrepresentation Analyses
For comparison of variant frequencies between disease and control groups, only variants from unrelated individuals were used. The PRIMUS software package was used to identify ORIGINAL RESEARCH ARTICLE nonrelated individuals among both BRIDGE control subjects without PAH and patients with PAH. 30 The number of unrelated control subjects was maximized by including either patients with other rare diseases or their unaffected relatives. The frequency of rare and predicted deleterious heterozygous EIF2AK4 variants in PAH index cases was also compared with publically available information in the ExAC database (http:// exac.broadinstitute.org). 26 This analysis provides the maximum estimate of the frequency of heterozygous EIF2AK4 variants in the ExAC database because variants in ExAC were assumed not to be in a compound heterozygous state.
Phenotypic Data Capture and CT Assessment
Paper and electronic patient records of patients with PAH were reviewed to capture demographic and phenotypic variables from the time of diagnosis and follow-up. Survival data for UK patients were obtained from recruiting centers through the NHS National Spine and local databases. Anonymized information was captured securely online with the free OpenClinica software, adapted for data capture specific to PAH.
CT images of the chest, when available, were reviewed independently by 2 cardiothoracic radiologists (A.S. and N.S.) with specialist imaging experience in pulmonary hypertension who were blinded to the underlying diagnoses with a customized proforma. Further information is provided in the supplemental materials and Tables IV and V in the online-only Data Supplement.
Statistical Analysis
Statistical analysis was performed in R (www.r-project.org). Further information is provided in the online-only Data Supplement.
Semiparametric Cox proportional hazard models were used to assess survival between groups with the survival package in R. Time from diagnosis to both death and death or transplantation was assessed. Age at diagnosis and sex were used as covariates in the models. To avoid immortal time bias arising from the inclusion of retrospectively recruited patients and prevalent patients, a sensitivity analysis was conducted. In this analysis, only prospectively recruited patients from the UK were included, and patients entered the risk set only from the time they consented to the study. Further information is provided in the online-only Data Supplement.
RESULTS
Study Patients
Whole-genome sequencing was performed on 932 patients recruited to the NIHR BRIDGE PAH study and 7134 control subjects without PAH recruited to other NIHR BRIDGE study cohorts. Fifty-two patients were excluded from further analysis because they did not have a clinical diagnosis of idiopathic PAH, heritable PAH, PVOD, or PCH ( Figure 1 ). The remaining 880 patients (of whom 872 were defined as unrelated index cases) consisted of 16 patients (1.8%) with a clinical diagnosis of PVOD/PCH, 56 (6.4%) with PAH and a family history of the disease (referred to as familial PAH), and 808 (91.8%) with idiopathic PAH and no known family history. One of the 16 patients with a clinical diagnosis of PVOD/PCH had an affected sister, whereas the remainder had the sporadic form of the disease.
BMPR2 Mutations in the PAH Cohort
Rare and predicted deleterious BMPR2 mutations (single-nucleotide variants, indels, and larger deletions) were found in 41 patients (73.2%) with familial PAH and 89 patients (11.0%) with idiopathic PAH. No BMPR2 mutations were found in patients with a clinical diagnosis of PVOD/PCH.
Rare and Predicted Deleterious EIF2AK4 Variants in the PAH Cohort
Sixty-nine rare and predicted deleterious EIF2AK4 single-nucleotide variants and indels were present in the NIHR BRIDGE study. No large deletions were found that affected the EIF2AK4 gene locus. The variants are summarized in Table VI in the online-only Data Supplement. Five of the 16 patients (31.3%) with clinically diagnosed PVOD/PCH carried biallelic EIF2AK4 mutations (2 homozygotes and 3 compound heterozygotes).
Twenty-five EIF2AK4 variants were also found in 19 patients (2.2%) diagnosed clinically with PAH, in whom there was no clinical suspicion of PVOD/PCH (5 homozygotes, 4 compound heterozygotes, and 10 heterozygotes; Table VII in the online-only Data Supplement). One of these patients with a homozygous EIF2AK4 mutation (c.3097C>T creating a premature stop codon) had a sister who had died of PAH. There was no reported family history of PVOD/PCH.
The remaining rare EIF2AK4 variants were found in a heterozygous state in 36 control subjects (0.5%). Four of these variants appeared in >1 control subject without PAH, and none were shared with patients with PAH.
Overrepresentation of Rare Heterozygous EIF2AK4 Variants in Patients With Idiopathic PAH Compared With Control Subjects
The proportion of patients with a clinical diagnosis of idiopathic PAH carrying heterozygous rare EIF2AK4 variants (1.2%) was significantly greater than the percentage of control subjects without PAH (0.5%; P=0.030). A similar overrepresentation in patients with idiopathic PAH was observed compared with allele frequencies in the ExAC database (0.6%; P=0.042). Two patients with idiopathic PAH with heterozygous rare EIF2AK4 variants also carried a rare and predicted deleterious BMPR2 mutation.
Phenotype of Patients With a Clinical Diagnosis of PAH and Biallelic EIF2AK4 Mutations
Patients with a clinical diagnosis of PAH and biallelic EI-F2AK4 mutations presented at a younger age (median, 29 years; interquartile range, 23-38 years) compared with patients without mutations in the PAH associated genes (51 years; IQR, 37-65 years; P=0.024; Table 1 ). Mean pulmonary artery pressure, cardiac output, and pulmonary vascular resistance were not significantly different between patients with PAH with biallelic EIF2AK4 mutations and the other groups. As previously reported, hemodynamic variables were significantly worse in patients with BMPR2 mutations compared with those without any mutations in these genes.
The Only 1 patient with a heterozygous rare and predicted deleterious EIF2AK4 variant (c.2516T>C) had a reduced Kco (54% predicted) with normal spirometry (FEV 1 , 102% predicted; FVC, 98% predicted; and total lung capacity, 100% predicted). There was mild paraseptal emphysema on thoracic CT (<5% of the lung parenchyma affected). This patient, a 44-year-old white man diagnosed with idiopathic PAH, also carried a rare and deleterious BMPR2 splice acceptor mutation (c.853-2A>G).
We questioned whether Kco was a predictor of biallelic EIF2AK4 mutations in the wider cohort. However, among patients with PAH with no mutations and normal spirometry (n=255), a reduced Kco (<50% predicted) was present in 65 patients (25.5%). In these patients with a reduced Kco and preserved spirometry, 90.8% were >50 years old at diagnosis, and 69.2% had a history of coronary artery disease, left ventricular dysfunction, or cardiovascular risk factors (diabetes mellitus, systemic hypertension, or hyperlipidemia). BMI indicates body mass index; CO, cardiac output; FEV 1 , forced expiratory volume in 1 second; FVC, forced vital capacity; Kco, transfer coefficient for carbon monoxide; mPAP, mean pulmonary artery pressure; PAH, pulmonary arterial hypertension; PCH, pulmonary capillary hemangiomatosis; PVOD, pulmonary venoocclusive disease; PVR, pulmonary vascular resistance; and S A o 2 , arterial oxygen saturation. *Also includes the 2 patients with a heterozygous EIF2AK4 variant and a BMPR2 variant. Data presented as median (interquartile range) unless indicated. Percentages were calculated from the number of patients for whom data were available as the denominator.
Given the high prevalence of a low Kco with preserved spirometry in the wider cohort, we restricted an analysis to patients <50 years of age who at the time of diagnosis had normal spirometry (n=164). Even in this group, a significant proportion (n=15, 9.1%) had a Kco <50% predicted (Figure 2 ). Eight of these 15 patients carried biallelic EIF2AK4 mutations. One patient with biallelic EIF2AK4 mutations was 70 years of age at diagnosis and subsequently did not meet this cutoff.
Among patients with normal spirometry, the presence of a Kco <50% predicted and age at diagnosis <50 years had a high sensitivity (0.889) and specificity (0.977) for identifying patients who carry biallelic EI-F2AK4 mutations; the positive predictive value was low (0.533). Nevertheless, in terms of the diagnostic yield, although genetic testing for biallelic EIF2AK4 mutations in the entire cohort of patients diagnosed clinically with PAH yielded a 1% detection rate, the presence of biallelic EIF2AK4 mutations in patients with PAH with a Kco <50% predicted with normal spirometry and <50 years of age at diagnosis was 53%.
CT Features of EIF2AK4 Mutation Carriers
Centrilobular ground glass opacification extent, mediastinal lymphadenopathy, and interlobular septal thickening are considered suggestive of PVOD/PCH. However, we found subtle or gross centrilobular ground glass opacification in 38% of patients diagnosed clinically with PAH and carrying no mutations (n=21) and 67% of patients with PAH with BMPR2 mutations (n=21). This was not significantly different compared with patients with a clinical diagnosis of PAH and biallelic EIF2AK4 mutations (86%, n=7) and patients with a clinical diagnosis of PVOD (50%, n=14). Gross interlobular septal thickening and mediastinal lymphadenopathy were significantly more frequent among patients with PAH and biallelic EIF2AK4 mutations (29% and 57%, respectively) and those with PVOD (64% and 79%) compared with patients with PAH and no mutation (5% and 0%) or BMPR2 mutations (5% and 10%). A radiological suspicion of PVOD/PCH was raised in 71% of those with PVOD, 57% of patients with a clinical diagnosis of PAH and biallelic EIF2AK4 mutations, 14% of patients with PAH with no mutation, and 5% of those with BMPR2 mutations (Table 2) .
A further CT analysis comparing patients with biallelic EIF2AK4 mutations (with a clinical diagnosis of PVOD/PCH or PAH; n=11) and those with a clinical diagnosis of PVOD but not carrying biallelic EIF2AK4 mutations (n=10) was made ( 
012).
However, pleural effusions were more common among those without a mutation (40%) compared with patients with biallelic EIF2AK4 mutations (0%; P=0.035). This may suggest that patients with biallelic EIF2AK4 mutations have a distinct radiological phenotype compared with patients with PVOD and no biallelic EIF2AK4 mutations.
Response to Pulmonary Artery Vasodilator Therapies
The response to pulmonary artery vasodilator therapies at 1 and 3 years was assessed for patients with a clinical diagnosis of PAH and biallelic EIF2AK4 mutations and the other patients with PAH included in the CT analysis. Patients with a clinical diagnosis of PAH and biallelic EIF2AK4 mutations did not improve their functional class at either 1 or 3 years after diagnosis, unlike the other PAH groups (Table X in the online-only Data Supplement).
Histological Features of a Biallelic EIF2AK4 Mutation Carrier
The explanted lungs of 1 patient diagnosed with idiopathic PAH but found to have a homozygous EIF2AK4 missense mutation (c.1795G>C, p.G599R) were as- Patients with forced expiratory volume in 1 second of expiration <80% predicted and forced vital capacity <80% predicted and diagnosed with PAH or pulmonary veno-occlusive disease (PVOD)/pulmonary capillary hemangiomatosis after 50 years of age were excluded from the plot.
sessed. The predominant histological feature was pulmonary arterial vasculopathy. The pulmonary arteries predominantly showed concentric and eccentric intimal fibrosis. No plexiform lesions were observed. Although infrequent, there was some fibrosis of the septal veins and venules, some of which were nearly completely occluded. Although there was evidence of capillary congestion, no capillary hemangiomatosis was observed (Figure 3) . The missense variant carried by this patient was not reported in the ExAC database, occurs in a conserved area of the genome (Genomic Evolutionary Rate Profiling score, 5.5), and was predicted to be deleterious (combined annotation-dependent depletion score, 32; PolyPhen-2 prediction of "probably damaging [1] ," sorting intolerant from tolerant prediction of "deleterious [0]"). The same homozygous mutation was also found in a second unrelated patient with a clinical diagnosis of idiopathic PAH.
Impact of Genotype on Survival
Eight hundred fifty-eight patients were included in the Cox proportional hazards model (Table XI and Figure  I in the online-only Data Supplement). Patients diagnosed clinically as having PAH with biallelic EIF2AK4 mutations had a shorter survival time from diagnosis compared with the BMPR2 mutation carriers (P<0.001) and those without any variants in PAH-associated genes (P<0.001). Age (P<0.001) and sex (P=0.001) also had a significant effect on survival, with male sex and older age at diagnosis associated with shorter survival in the model. Similar results were obtained in the assessment of time to death or transplantation (Table XII in the online-only Data Supplement). In the sensitivity analysis, including only prospectively recruited UK patients, only 2 events occurred in the biallelic EIF2AK4 group. Thus, no significant difference was observed in mortality between patients diagnosed clinically as having PAH with biallelic EIF2AK4 mutations and patients with BMPR2 mutations (P=0.215) or patients without any variants in PAH-associated genes (P=0.282; Table XIII in the onlineonly Data Supplement).
DISCUSSION
This is the first study to analyze the frequency of EI-F2AK4 rare variation in a large cohort of patients with PAH and to make detailed phenotypic and radiological assessments. Previously, the presence of biallelic EI-F2AK4 mutations was reported in patients with a clear As expected, we identified a high frequency of biallelic EIF2AK4 mutations in patients with a clear clinical presentation of PVOD/PCH. However, we also found biallelic EIF2AK4 mutations in patients with a clinical diagnosis of PAH. The discovery of biallelic EIF2AK4 mutations in PVOD/ PCH raised the possibility of rapid molecular diagnosis in the majority of patients with familial and up to 25% of patients with sporadic PVOD/PCH. 14, 15 In the present study, the presence of biallelic EIF2AK4 mutations was associated with a poor prognosis, even in patients who have a clinical diagnosis of PAH and who did not develop pulmonary edema in response to pulmonary artery vasodilator therapies. Therefore, early identification of these patients through genetic testing may prompt early referral for lung transplantation similar to patients with clinically diagnosed PVOD/PCH. 18 The presence of biallelic EIF2AK4 mutations in patients with a clinical diagnosis of PAH raises the question whether EIF2AK4 mutations can cause classic idiopathic PAH or whether there are cases of PVOD/ PCH caused by EIF2AK4 mutations that are wrongly classified even by expert centers. We further show that phenotypic, radiological, and histological assessments can be difficult to interpret. The presence of subtle or infrequent features may lead to an incorrect diagnosis of PAH in patients with biallelic EIF2AK4 mutations. This study suggests that patients with pathogenic biallelic The patient was of Pakistani origin and did not have a family history of PAH or pulmonary veno-occlusive disease (PVOD). At presentation, he was 22 years old and had a reduced transfer coefficient for carbon monoxide (Kco; 31% predicted) despite preserved spirometry. High-resolution computed tomography of his chest showed subtle but extensive (50%-75% involvement) ground glass opacification. No interlobular septal thickening or mediastinal lymphadenopathy was observed. No suspicion of PVOD/pulmonary capillary hemangiomatosis (PCH) was raised from the radiological appearances. Histopathology was reviewed by 2 independent pathologists, each confirming the predominant histological pattern to be one of pulmonary arterial vasculopathy. The pulmonary arteries showed eccentric and concentric intimal fibrosis and medial hypertrophy (A and B), as well as some lesions with features of recanalized thrombus (C). Several concentrically muscularized arterioles were also observed (D). No complex plexiform lesions were present. There was patchy thickening of the alveolar septa with capillary congestion and pigmented intra-alveolar macrophages similar to PCH (E and F). Venous remodeling was difficult to trace and infrequent but present. Fibrous thickening of the intima in septal veins (G and I) and a microvessel (H).
EIF2AK4 mutations may present with a spectrum of phenotypic, radiological, and histological features that can overlap with PAH.
Patients with PAH with biallelic EIF2AK4 mutations demonstrated a reduced Kco despite normal spirometry, which is characteristic of patients with PVOD/PCH. The reduced Kco likely reflects widespread reduction in alveolar gas exchange caused by endothelial proliferation and patchy thickening of the blood-gas barrier by the process of capillary hemangiomatosis. Ultrastructural thickening of the capillary basement membrane may also play a role. 33 In keeping with previous reports in PVOD/PCH, we also show that patients with PAH with biallelic mutations in EIF2AK4 are younger at diagnosis than patients with either BMPR2 mutations or no known mutation. 14, 20 However, the presence of these characteristic features has a low positive predictive value for the identification of patients with biallelic EIF2AK4 mutations.
In contrast to previous descriptions of patients with PVOD, none of the patients with clinically diagnosed PAH and biallelic EIF2AK4 mutations developed pulmonary edema in response to pulmonary artery vasodilator therapies. For example, intravenous prostanoids were used in 50% of these patients. In patients with classic PVOD, pulmonary edema with intravenous prostanoids has been reported in up to 44% of patients after a median treatment duration of just 9 days. 4 Presumably, the extent and severity of the pulmonary venous involvement in these patients might underlie the differing responses to prostanoids.
It is generally considered that high-resolution CT imaging is a useful noninvasive test to assist in the diagnosis of suspected PVOD/PCH. 11 Although there was an increased prevalence of mediastinal lymphadenopathy and interlobular septal thickening in patients with PAH with biallelic EIF2AK4 mutations, we found that radiological features at the time of diagnosis could not accurately determine the underlying genotype. 6 The differing radiological features of all patients with biallelic EIF2AK4 mutations compared with patients with PVOD without mutations is of interest. This may reflect differences between the younger-onset genetic cases of PVOD compared with the predominantly older group of patients without EIF2AK4 mutations in whom other nongenetic factors such as exposure to inorganic solvents may play an important role. 34 Histological examination (usually postmortem or from explanted lungs) is often considered essential for diagnostic confirmation of PVOD/PCH but may be confounded by the heterogeneous nature of vascular pathology. 35 Surgical biopsy of the lung in patients with severe PAH is contraindicated, and a limitation of this study is that lung tissue from only 1 patient with biallelic EIF2AK4 mutations was available for analysis. This patient had a rare and predicted deleterious homozygous missense mutation in EIF2AK4. The predominant feature on assessment of the explanted lung tissue was pulmonary arteriopathy, as usually seen in PAH. Although only infrequent, fibrosis of the septal venules and the possible presence of siderophages in the alveolar space were observed. These features are found in patients with PVOD/PCH. This case supports the hypothesis that patients with biallelic EIF2AK4 mutations may present with a spectrum of venous and arterial involvement.
There are increasing reports of phenotypic, radiological, and histological similarities between PAH and PVOD/PCH. 6, 12, 13 Tenorio et al 31 reported a homozygous missense mutation in EIF2AK4 in a large kindred of Iberian Romani with apparent heritable PAH. This kindred is likely to have PVOD/PCH because these diagnoses were not confirmed histologically and PVOD was suspected in half the patients. More recently, Best et al 32 also report 2 sisters with apparent heritable PAH-carrying biallelic EIF2AK4 mutations. These patients also had a reduced Kco but had not had high-resolution CT assessment of their lung parenchyma, which may have altered their clinical diagnosis. Taken together, these previous reports are compatible with the findings in this larger cohort that patients with a clinical presentation of idiopathic or heritable PAH may in fact have underlying PVOD/PCH as determined by genetic analysis.
A strength of this study is the centralized reporting of radiographic features. However, the data collection was retrospective and incomplete in some cases. Assessing rare diseases such as PAH and PVOD/ PCH with a prospective study recruiting incident cases would take a prohibitively long time. This is especially true for the assessment of survival and response to therapy. In this study including prevalent and retrospectively recruited patients, we demonstrated a worse prognosis in patients with a clinical diagnosis of PAH and biallelic EIF2AK4. However, the inclusion of prevalent and retrospectively recruited patients can introduce bias such as immortal time bias, when there are long periods between diagnosis and enrollment in the study. The effect of immortal time bias and other confounders such as the inclusion of prevalent and incident cases can be difficult to predict. All groups are likely to include patients who died before study enrollment and thus would not feature in any analysis. When we attempted to eliminate these sources of bias in a sensitivity analysis restricted to prospectively recruited patients from the United Kingdom, the study did not have sufficient power to show a difference in survival between different genotypes. Further studies of survival and response to therapy are needed to definitively show whether misclassified patients with PAH with biallelic EIF2AK4 mutations and patients with classic PVOD with these mutations have a similarly poor prognosis. 
ORIGINAL RESEARCH ARTICLE
The genetic architecture of idiopathic and heritable PAH remains to be fully elucidated. Ongoing analysis of whole-genome sequence data in our cohort is likely to reveal novel rare variation underlying this condition. Mutations in BMPR2 account for ≈17% of cases of idiopathic PAH, and other known PAH genes account for ≈1% to 2% of all cases. 21, 36 In the present study, BMPR2 mutations were found in 11% of patients without a family history of PAH. It is worth noting that patients with the sporadic form of the disease with no reported family history represent a higher burden of BMPR2 mutations (n=89) compared with those with a family history (n=49). This has important implications for clinical genetic testing in patients with sporadic and familial disease.
In previous studies, mutations in both EIF2AK4 alleles are required to cause PVOD and PCH. 14, 15 In autosomal recessive disorders, it is unusual for the heterozygous state to manifest the disease phenotype, and heterozygous EIF2AK4 variants thus would not be expected to be pathogenic. In this study, we found a significant overrepresentation of heterozygous rare and predicted deleterious EIF2AK4 variants in patients with PAH compared with control subjects and report 2 patients with rare variants in both BMPR2 and EIF2AK4. Recently, the possibility that heterozygous EIF2AK4 variants influence the penetrance of BMPR2 mutations has been raised in a single family with PAH. 37 Further studies are required to determine whether heterozygous EIF2AK4 variants contribute to pathogenesis in PAH.
CONCLUSIONS
We demonstrate that biallelic EIF2AK4 mutations are found in patients diagnosed clinically with idiopathic and familial PAH. These patients may have subtle features suggestive of PVOD/PCH on close inspection and are likely to have underlying PVOD/PCH. The spectrum of phenotypic, radiological, and histological features found in patients with biallelic EIF2AK4 mutations made by current clinical assessments is wider and less clear-cut than previously recognized. This may lead to misclassification of patients as having PAH rather than PVOD and hinders accurate risk stratification. Ascertaining the EIF2AK4 mutation status of patients through clinical genetic testing provides additional information to aid risk stratification and to guide management. In a young patient presenting with apparent PAH, the presence of a low Kco with normal spirometry strongly suggests the presence of underlying biallelic EIF2AK4 mutations. Patients with an apparent clinical diagnosis of PAH and biallelic EIF2AK4 mutations have a worse prognosis compared with patients with BMPR2 mutations and those without these mutations. Clinical genetic testing should aid identification of this high-risk group and facilitate early referral for lung transplantation and appropriate management.
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